Organization (Other)
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov lists Institut National de la Santé Et de la Recherche Médicale, France as lead sponsor of 376 trials. It has 184 active development programs and 38 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 34 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 34 in 2026 and about 36 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.
This page covers Institut National de la Santé Et de la Recherche Médicale, France: 376 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (563)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 33 |
| Dementia | 30 |
| COVID-19 | 29 |
| Parkinson Disease | 29 |
| Stroke | 29 |
Showing 5 of 563 disease areas.
Trials by start year as sponsor or collaborator (31)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 34 |
| 2025 | 34 |
| 2024 | 46 |
| 2023 | 50 |
| 2022 | 60 |
| 2021 | 66 |
| 2020 | 62 |
| 2019 | 61 |
| 2018 | 40 |
| 2017 | 65 |
Showing 10 of 31 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 24 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 270 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (184)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sodium Chloride 0.9% Inj | Ischemic Stroke | Phase 3 | 1 |
| Sodium Chloride 0.9% Inj | Stroke | Phase 3 | 1 |
| Lidocaine 20mg/ml | Ischemic Stroke | Phase 3 | 1 |
| Lidocaine 20mg/ml | Stroke | Phase 3 | 1 |
| Levobupivacaine Hydrochloride 1.25 MG/ML | Ischemic Stroke | Phase 3 | 1 |
Showing 5 of 184 active programs.
Approved assets (38)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PNNS guidelines | 1 |
| Anti-H1N1v Vaccine | 1 |
| Venlafaxine Extended Release | 1 |
| Prostaglandin E2 | 1 |
| LEUPRORELIN ACETATE | 1 |
Showing 5 of 38 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 49% hit target (n=188) | 34% on time (n=178) |
Journals published in (969)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| PloS one | 57 |
| The New England journal of medicine | 54 |
| Neurology | 36 |
| Lancet (London, England) | 35 |
| The American journal of clinical nutrition | 33 |
Showing 5 of 969 journals.
Organization relationships (212)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| URC-CIC Paris Descartes Necker Cochin | Co sponsors trial with | 15 |
| University Hospital, Lille | Co sponsors trial with | 13 |
| University Hospital, Grenoble | Co sponsors trial with | 12 |
| University Hospital, Toulouse | Co sponsors trial with | 12 |
| University Hospital, Bordeaux | Co sponsors trial with | 12 |
Showing 5 of 212 relationships.
Latest dated events (983)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 983 events.
Biomarker capability evidence (812)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCB1 | Trial collaborator | Named in trial inclusion criteria |
| ABCC8 | Trial collaborator | Named in trial inclusion criteria |
| ABO | Trial collaborator | Named in trial inclusion criteria |
| ACE | Trial collaborator | Named in trial inclusion criteria |
| ADARB1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 812 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.